Biolidics limited, a Singapore-based medical technology company has been hogging the limelight recently after inking a US distribution deal for its Covid-19 test kits. Its shares have been on a roller coaster ride, reaching as high as S$0.84 on 22 April before dropping back to the current level of S$0.45 after the disclosure of its US distribution partner.

Is the fuss over the stock hugely overhyped or is this a multi-bagger gem in the making?

I thought it will be interesting to do a little “sleuthing” of the company to see if it is worth an investment.

Do note that this article is purely an opinion piece and not one construed to recommend a sell or buy off the counter.

I believe the investment thesis of Biolidics rests on its foray into the US market for its COVID-19 rapid test kit. However, before that, a summary of what happened in